Investor Relations

About Us

American CryoStem Corporation (CRYO) was founded in 2008 and commenced trading on the OTC Markets in 2011. The company has evolved to become a Bio-Technology pioneer, focusing on standardizing adipose tissue-derived stem cell technologies for the fields of Regenerative and Personalized Medicine meant to help heal and restore function to the human body. Our Investors help drive our innovation and share our passion for Bio-Technology. 


We look forward to helping people live their best lives possible. 

The Company operates a state-of-art, FDA-registered, clinical laboratory in Monmouth Junction, New Jersey and licensed laboratories in Hong Kong, China and Tokyo, Japan, which operate on our proprietary platform, dedicated to the collection, processing, bio-banking of adipose tissue (fat) and culturing, differentiation of adipose-derived stem cells (ADSCs) for use in regenerative medicine.

The Company’s R&D efforts are focused on the discovery, development and commercialization of ADSCs with synergistic partnerships to develop regenerative medicine applications and new intellectual property.

January 6, 2023
American CryoStem Announces FDA Approval of IND to Commence Phase I Clinical Trial for Long COVID/Post-Acute Sequelae of SARS-CoV-2 (PASC)
EATONTOWN, NJ / ACCESSWIRE /January 6, 2022 / American CryoStem Corporation (OTC PINK: CRYO), a clinical-stage therapeutics company with a proprietary end-to-end core biotechnology platform of tissue-based cellular technologies that powers its clinical pipeline announced today that it has received U.S. Food and Drug Administration (FDA) approval to proceed with a Phase I Clinical Trial for the treatment of Long COVID/PASC.
December 22, 2022
American CryoStem Announces the Addition of Agustin Legido, MD, PhD, MBA to its Advisory Board
EATONTOWN, NJ December 22, 2022; American CryoStem Corporation (OTC: CRYO), a clinical-stage therapeutics company with a proprietary end-to-end core biotechnology platform of tissue-based cellular technologies powering its clinical pipeline, announced today that Agustin Legido, MD, PhD, MBA has joined its Scientific and Medical Advisory Board.
March 4, 2022
American CryoStem Announces Patient Treatment Status for its Phase I Clinical Trial for Post-Concussion Syndrome (PCS)
EATONTOWN, NJ / ACCESSWIRE / March 4, 2022 American CryoStem Corporation (OTC: CRYO) a clinical stage biotechnology company, global licensor, and a pioneer in autologous cellular processing and cellular therapies, announced today that it has reached the midway point of its ATCell™ autologous mesenchymal stem cell therapy for Phase I Clinical Trial for Post-concussion syndrome (PCS).

Pipeline Growth Strategy 

We use our patented intellectual property to develop safe and effective cellular medicine products and applications for indications that represent a large unmet need globally. Our therapeutic pipeline of products and applications is based on technologies developed both in-house and obtained through licensing and collaboration arrangements with biotechnology companies.

We intend to utilize our comprehensive cellular platform to support cellular products related to gender, age, nationality, orthopedic applications and disease with partners that can efficiently develop treatments without having to rediscover and recreate the underlying technology for each new product.


An early adopter of utilizing adipose tissue as a stem cell source we have designed every process and product to standardize, validate and commercialize our platform.


Patented, modular, platform technology allows complete control of the stem cell processing and manufacturing chain for optimal standardized cellular characteristics.


Allowing a patient to improve their quality of life by easily preparing for their current or future regenerative medicine needs by utilizing our cellular platform with multiple products, (bio-insurance) allowing for usage at every stage of life.

Our Role in the Industry

Regenerative & Personalized Medicine holds the promise of regenerating damaged tissues and organs in the body by stimulating the body’s own repair mechanisms to heal previously irreparable tissues and organs. The industry currently has three major categories where our platform and stem cell products participate;